Download PDF

1. Company Snapshot

1.a. Company Description

ClearPoint Neuro, Inc.operates as a medical device company primarily in the United States.The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance.


It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite.It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco.The company was formerly known as MRI Interventions, Inc.


and changed its name to ClearPoint Neuro, Inc.in February 2020.ClearPoint Neuro, Inc.


was incorporated in 1998 and is headquartered in Solana Beach, California.

Show Full description

1.b. Last Insights on CLPT

ClearPoint Neuro's recent performance was driven by several positive factors. The company's Q2 2025 results showcased record revenue and substantial cash infusion, highlighting its 'Fast. Forward.' strategy. Additionally, the FDA clearance for the ClearPoint Prism Neuro Laser Therapy System to include 1.5T MRI guidance expanded its market opportunity. Partnership milestones, including commercial infusions in the US and progress in gene therapy delivery, also contributed to growth. Furthermore, the appointment of Dr. Paul Larson as Chief Medical Officer and positive data from partner uniQure's Huntington's Disease trials have bolstered the company's prospects.

1.c. Company Highlights

2. ClearPoint Neuro Rockets into 2026 Growth

ClearPoint Neuro delivered a robust 2025, reporting $37 million in revenue—an 18% lift over 2024—while maintaining a solid 61% gross margin. Earnings per share slipped to a modest -$0.27 versus analyst expectations of -$0.22, reflecting higher R&D spend of $13.9 million and the impact of recent acquisitions [Danilo D'Alessandro, CFO].

Publication Date: Apr -17

📋 Highlights
  • 2025 Revenue Growth:: Total revenue reached $37 million in 2025, marking an 18% increase from 2024, driven by biologics/drug delivery ($19 million, +10%) and neurosurgery navigation ($14.8 million).
  • 2026 Revenue Guidance:: Projected revenue of $52–56 million for 2026, reflecting strategic focus on FDA-approved rare diseases and integration of the Eris acquisition.
  • Financial Strength:: Ended 2025 with $45.9 million in cash, a $25.8 million increase from 2024, fueled by $51.4 million in equity/notes and $1.1 million from the Eris acquisition.
  • Biopharma Partnerships:: Collaborates with 60+ biopharma partners, supporting over 25 clinical trials across 15+ indications, with 10 programs under FDA expedited review.
  • Market Expansion Strategy:: Targets a $1 billion market via two phases: "Fast Forward" (20% of $1B market) and "Essential Everywhere" (cell/gene therapy delivery), aiming for $200 million in annual revenue by 2026.

2025 Revenue Surge and Margin Strength

The company’s biologics and drug delivery segment grew 10% to $19 million, complemented by neurosurgery navigation revenue reaching $14.8 million. These gains, coupled with disciplined cost management, underpin the 61% gross margin that outpaces many peers in the neuro‑interventional space.

Cash Position and Capital Structure

ClearPoint closed 2025 with $45.9 million in cash and equivalents, a $25.8 million increase driven by $51.4 million in net proceeds from notes and a stock offering, plus $1.1 million in cash from the Eris acquisition. Net debt/EBITDA stands at -0.55, indicating a cash‑rich balance sheet poised for growth.

Product Pipeline and Market Expansion

The firm now boasts four expanding product categories—pre‑commercial biologics, neurosurgery navigation, laser therapy, and neurocritical care—supported by an IP portfolio, global regulatory approvals, and an installed base of 150+ centers. Over 60 biopharma partners are active in 25+ trials, covering more than 15 indications, with 10 partner programs under FDA expedited review.

Strategic Growth Phases: Fast Forward & Essential Everywhere

Phase One, “Fast Forward,” targets a $1 billion market, aiming for 20% penetration, $200 million in annual revenue, and cash breakeven. Phase Two, “Essential Everywhere,” focuses on creating a new market for cell and gene therapy delivery, leveraging the company’s ecosystem to support biopharma partners treating severe neurological diseases.

2026 Guidance and Investor Outlook

Guidance for 2026 has been tightened, with revenue projected at $52–$56 million—double‑digit growth across all four segments—reflecting FDA discussions on rare disease approvals and integration priorities from the Eris acquisition. The company balances organic expansion with strategic acquisitions, expecting all segments to grow in the high‑teens.

Valuation Snapshot

Current valuation metrics show a P/E of -11.64 and a P/S of 8.45, while EV/EBITDA sits at -14.49. The negative ROIC of -27.56 and ROE of -122.17 underscore the early‑stage nature of the business, yet the cash‑positive stance and expanding pipeline suggest upside potential if execution aligns with guidance.

3. NewsRoom

Card image cap

ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint

Apr -20

Source: accessnewswire.com

Card image cap

ClearPoint Neuro, Inc. (CLPT) Q4 2025 Earnings Call Transcript

Mar -17

Source: seekingalpha.com

Card image cap

ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates

Mar -17

Source: zacks.com

Card image cap

ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results

Mar -17

Source: accessnewswire.com

Card image cap

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2025 Results March 17, 2026

Mar -06

Source: accessnewswire.com

Card image cap

CLPT Gets EU MDR Certification for ClearPoint Navigation Software

Jan -27

Source: zacks.com

Card image cap

ClearPoint Neuro: From Validation To Scale

Jan -27

Source: seekingalpha.com

Card image cap

ClearPoint Neuro Gets EU Green Light For Updated Brain Surgery Software

Jan -23

Source: benzinga.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.61%)

6. Segments

Biologics and Drug Delivery - Services and License

Expected Growth: 9.95%

Strong demand for biologics and drug delivery services, driven by increasing prevalence of chronic diseases and growing need for innovative treatments. ClearPoint Neuro's expertise in neurosurgical navigation and therapy delivery enables precise and minimally invasive procedures, fueling 9.95% growth. Partnerships and licensing agreements with pharmaceutical and biotech companies further accelerate growth.

Functional Neurosurgery Navigation and Therapy - Disposable Products

Expected Growth: 9.27%

Strong demand for minimally invasive neurosurgical procedures, increasing adoption of ClearPoint Neuro's navigation and therapy systems, and growing awareness of functional neurosurgery benefits drive 9.27% growth. Additionally, advancements in disposable product technology, expanding indications for neurosurgical interventions, and strategic partnerships contribute to the segment's rapid expansion.

Biologics and Drug Delivery - Disposable Products

Expected Growth: 9.27%

ClearPoint Neuro's Biologics and Drug Delivery - Disposable Products segment growth of 9.27% is driven by increasing demand for minimally invasive neurosurgical procedures, advancements in gene therapy, and growing adoption of disposable products in neurointerventions, coupled with the company's strong R&D pipeline and strategic partnerships.

Capital Equipment and Software - Services

Expected Growth: 9.03%

ClearPoint Neuro's 9.03% growth in Capital Equipment and Software - Services is driven by increasing adoption of minimally invasive neurosurgical procedures, rising demand for precision-guided therapies, and expansion into new markets. Additionally, the company's innovative product offerings, strategic partnerships, and growing installed base of biopsies and laser ablation systems contribute to its growth momentum.

Functional Neurosurgery Navigation and Therapy - Services

Expected Growth: 10.43%

ClearPoint Neuro's 10.43% growth in Functional Neurosurgery Navigation and Therapy Services is driven by increasing adoption of minimally invasive procedures, advancements in neuro-navigation technology, growing demand for precise lesioning and ablation, and expanding indications for neurosurgical interventions, such as epilepsy and Parkinson's disease treatments.

Capital Equipment and Software - Systems and Software Products

Expected Growth: 9.03%

ClearPoint Neuro's 9.03% growth in Capital Equipment and Software - Systems and Software Products is driven by increasing adoption of minimally invasive neurosurgical procedures, growing demand for precision-guided therapies, and expansion into new markets. Additionally, advancements in AI-powered navigation and planning software, and strategic partnerships with hospitals and research institutions, contribute to the segment's growth.

7. Detailed Products

Neuro Navigation

A surgical navigation system that provides real-time visualization and guidance during neurosurgical procedures.

Intraoperative Imaging

A suite of imaging technologies that provide real-time visualization during neurosurgical procedures.

Stereotactic Systems

A range of systems for stereotactic neurosurgery, including frame-based and frameless options.

Neurodiagnostics

A range of diagnostic tools for neurologists and neurosurgeons, including EEG and EMG systems.

Surgical Planning Software

Advanced software for pre-operative planning and simulation of neurosurgical procedures.

8. ClearPoint Neuro, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

ClearPoint Neuro, Inc. faces moderate threat from substitutes, as there are limited alternative treatments for brain disorders, but ongoing research and development may lead to new substitutes in the future.

Bargaining Power Of Customers

Customers have limited bargaining power due to the specialized nature of ClearPoint Neuro, Inc.'s products and services, which are critical for treating brain disorders.

Bargaining Power Of Suppliers

Suppliers of raw materials and components have moderate bargaining power, as ClearPoint Neuro, Inc. relies on a few key suppliers, but there are alternative sources available.

Threat Of New Entrants

The threat of new entrants is low due to the high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise.

Intensity Of Rivalry

The medical device industry is highly competitive, with several established players, and ClearPoint Neuro, Inc. faces intense rivalry in the market for brain disorder treatments.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 32.88%
Debt Cost 3.95%
Equity Weight 67.12%
Equity Cost 8.81%
WACC 7.21%
Leverage 48.99%

11. Quality Control: ClearPoint Neuro, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Rapid Micro Biosystems

A-Score: 4.2/10

Value: 7.1

Growth: 3.6

Quality: 3.4

Yield: 0.0

Momentum: 10.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
NeuroOne Medical Technologies

A-Score: 4.0/10

Value: 6.8

Growth: 5.7

Quality: 4.2

Yield: 0.0

Momentum: 6.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
ClearPoint Neuro

A-Score: 3.9/10

Value: 6.0

Growth: 4.4

Quality: 4.1

Yield: 0.0

Momentum: 8.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Cytek Biosciences

A-Score: 3.7/10

Value: 5.7

Growth: 7.0

Quality: 4.0

Yield: 0.0

Momentum: 3.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Accelerate Diagnostics

A-Score: 3.4/10

Value: 10.0

Growth: 5.4

Quality: 5.0

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Pulmonx

A-Score: 3.1/10

Value: 8.5

Growth: 4.7

Quality: 4.2

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

11.06$

Current Price

11.06$

Potential

-0.00%

Expected Cash-Flows